Inhibikase Therapeutics (NYSE:IKT) PT Lowered to $23.00

Inhibikase Therapeutics (NYSE:IKT) had its price target trimmed by HC Wainwright from $27.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.87) EPS, FY2025 earnings at ($1.47) EPS and FY2026 earnings at ($1.46) EPS.

Inhibikase Therapeutics Stock Down 1.1 %

NYSE:IKT opened at $1.81 on Tuesday. Inhibikase Therapeutics has a 52-week low of $0.79 and a 52-week high of $4.35. The stock has a fifty day simple moving average of $1.88 and a 200-day simple moving average of $1.78.

Inhibikase Therapeutics (NYSE:IKT) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.15. Inhibikase Therapeutics had a negative net margin of 5,886.15% and a negative return on equity of 147.03%. As a group, research analysts predict that Inhibikase Therapeutics will post -1.87 EPS for the current year.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.